Cross-Protective Efficacy of a Prophylactic<i>Leishmania donovani</i>DNA Vaccine against Visceral and Cutaneous Murine Leishmaniasis

Aguilar-Be, Ingrid; Zardo, Renata da Silva; Souza, Edilma Paraguai de; Borja-Cabrera, G.P.; Rosado-Vallado, Miguel; Mut-Martı́n, Mirza; García-Miss, María del Rosario; Palatnik-de-Sousa, Clarisa B.; Dumonteil, Eric

doi:10.1128/iai.73.2.812-819.2005

Cited by 113 publications

(109 citation statements)

References 50 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…Signifi cant protection is not usually achieved when animals are immunized with recombinant proteins in the absence of adjuvants. These fi ndings have been corroborated by studies evaluating other well-known protective antigens against leishmaniasis (31) (32) (40) (54) .…”

Section: Tablesupporting

confidence: 69%

“…Kinetoplastid membrane protein-11 (KMP-11), a highly conserved protein expressed in different Leishmania species, was also verifi ed as protective against L. donovani infection in hamsters (51) (52) . In addition, the nucleoside hydrolase 36kDa (NH36) antigen was shown to be protective against Leishmania infantum, Leishmania mexicana, and Leishmania amazonensis species in BALB/c mice, indicating its potential as a heterologous vaccine to protect against different Leishmania species (53) (54) .…”

Section: Second-generation Vaccines Against Visceral Leishmaniasismentioning

confidence: 99%

See 1 more Smart Citation

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Duarte

Lage

Martins

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Visceral leishmaniasis (VL) is one of the most important tropical diseases worldwide. Although chemotherapy has been widely used to treat this disease, problems related to the development of parasite resistance and side effects associated with the compounds used have been noted. Hence, alternative approaches for VL control are desirable. Some methods, such as vector control and culling of infected dogs, are insuffi ciently effective, with the latter not ethically recommended. The development of vaccines to prevent VL is a feasible and desirable measure for disease control; for example, some vaccines designed to protect dogs against VL have recently been brought to market. These vaccines are based on the combination of parasite fractions or recombinant proteins with adjuvants that are able to induce cellular immune responses; however, their partial effi cacy and the absence of a vaccine to protect against human leishmaniasis underline the need for characterization of new vaccine candidates. This review presents recent advances in control measures for VL based on vaccine development, describing extensively studied antigens, as well as new antigenic proteins recently identifi ed using immuno-proteomic techniques.

show abstract

Section: Tablesupporting

confidence: 69%

Section: Second-generation Vaccines Against Visceral Leishmaniasismentioning

confidence: 99%

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Duarte

Lage

Martins

et al. 2016

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…There is also progress in characterization of defined antigens protective against VL in animal models as sub-unit or DNA vaccines such as KMP11, HASPB, A2 and CPB [21][22][23][24][25][26][27], whereas there are still only a limited number of bona fide vaccine candidates to combat this disease and no vaccine is available for human use yet. We have recently identified a number of L. infantum Ags by serological screening using sera from L. infantum-infected hamsters [28].…”

Section: Introductionmentioning

confidence: 99%

Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant

Goto

Bogatzki

Bertholet

et al. 2007

Vaccine

View full text Add to dashboard Cite

We present here the identification and characterization of Leishmania sterol 24-c-methyltransferase (SMT), as well as data on protection of mice immunized with this Ag formulated in MPL ® -SE. Serological evaluation revealed that SMT is recognized by VL patients. C57BL/6 mice immunized with this vaccine candidate plus MPL ® -SE showed Ag-specific Th1 immune responses characterized by robust production of IFN-γ upon specific Ag re-exposure in vitro. Upon challenge with L. infantum, mice immunized with SMT plus MPL ® -SE showed significant lower parasite burdens in both spleens and livers compared with non-immunized mice or mice injected with adjuvant alone. The results indicate that SMT/MPL ® -SE can be an effective vaccine candidate for use against VL.

show abstract

“…In the study of Gurunathan et al 2005), L. donovani DNA vaccines of NH36, showed better prophylactic efficacy than recom-binant protein of NH36 plus FML and Saponin against cutaneous and visceral Leishmaniasis in mice. Therefore, the DNA vaccine has been introduced as a good candidate for a cross-immunity against Leishmania species (21).…”

Section: Discussionmentioning

confidence: 99%

Immunization with KMP11-NTGP96-GFP Fusion of Leishmania major Induced Th1 Platform Immune Response in Susceptible BALB/c mice

Dalimi

Nasiri

2016

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Leishmaniasis has been known as an endemic disease since ancient times in Iran. Cell-mediated immunity plays a decisive role in Leishmaniasis. A promising vaccine against Leishmania could stimulate the Th1 immune response.Objectives: In the present study, the cellular immunogenicity of the pEGFP-N1, pEGFP-KMP and KMP11-NTGP96-GFP fusion in induction of Th1 platform immune response was evaluated in susceptible BALB/c mice. Methods:Recombinant plasmid construction of pEGFP-N1, pEGFP-KMP and KMP11-NTGP96-GFP fusion was prepared. The mice were assigned to four groups (each 15) and immunization was performed with three times (0, 21 and 42 days) with PBS, pEGFP-N1, pEGFP-KMP and pEGFP-KMP-GP96 (FUSION), subcutaneously via footpad. Cytokines assay was performed a day before and seven weeks following immunization.Results: According to the results, the level of cytokines interferon-gamma (IFN-γ) and interleukin (IL)-4, and ratio of IFN-γ /IL4 was changed among different groups of mice before and seven weeks after immunization. The cytokines were increased significantly in the groups that received pEGFP-KMP and pEGFP-KMP-GP96 (FUSION) compared to PBS and pEGFP-N1 groups (P < 0.05). Conclusions:In conclusion, pEGFP-KMP-GP96 (FUSION) induced Th1 platform immune response against Leishmania major (MRHO/IR/75/ER) infection.

show abstract

Cross-Protective Efficacy of a ProphylacticLeishmania donovaniDNA Vaccine against Visceral and Cutaneous Murine Leishmaniasis

Cited by 113 publications

References 50 publications

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant

Immunization with KMP11-NTGP96-GFP Fusion of Leishmania major Induced Th1 Platform Immune Response in Susceptible BALB/c mice

Contact Info

Product

Resources

About